EU To Suspend 17-OHPC Preterm Birth Drugs A Year After US Pulled Makena
Executive Summary
17-OHPC medicines are to be pulled from the market in Europe due to a potential link with cancer and the lack of efficacy data. The move comes around a year after the US regulator withdrew its approval of a similar drug from Covis.